Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Breast Neoplasms 3Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × dalotuzumab × Clear all
NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00694356 2018-08-08

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 13 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡